ClinicalTrials.gg

Program

lumateperone

Also written as “Lumateperone”, “ITI-007” and “Lumateperone high dose”.

Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Major · Autism Spectrum Disorder · Alzheimer Disease, led by Johnson & Johnson.

Furthest: phase 3, since Oct 31, 201425 company-led studies, 6 open or runningNext primary completion: Apr 5, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson256 open or runningphase 3since Oct 31, 2014Dec 16, 2011Apr 5, 2027phase 3 · NCT05850689

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since Dec 16, 2011.

  1. Aug 11, 2017Phase 3 study in Bipolar DisorderNCT03249376 · 381 enrolled · United States, Bulgaria, Colombia and more
  2. Feb 24, 2020Phase 3 study in Bipolar DisorderNCT04285515 · 488 enrolled · United States, Bulgaria, Russian Federation and more
  3. Feb 26, 2021Phase 1 study in SchizophreniaNCT04779177 · 26 enrolled · United States
  4. Jun 30, 2021Phase 3 study in SchizophreniaNCT04959032 · 592 enrolled · United States, Bulgaria, Poland and more
  5. Jul 22, 2021Phase 3 study in Depressive Disorder, MajorNCT04985942 · 485 enrolled · United States, Bulgaria, Czechia and more
  6. Sep 20, 20212 phase 3 studies in Depressive Disorder, MajorNCT05061719, NCT05061706
  7. Apr 28, 2023Phase 3 study in Depressive Disorder, MajorNCT05850689 · 470 planned · United States, Bulgaria, France and more
  8. Jan 19, 2024Phase 3 study in SchizophreniaNCT06229210 · 300 planned · United States, Colombia, Serbia
  9. Apr 15, 2024Phase 3 study in Bipolar DisorderNCT06372964 · 384 planned · United States, Colombia, India and more
  10. Jun 12, 20242 phase 3 studies in Bipolar DisorderNCT06462612, NCT06462586
  11. Aug 14, 2024Phase 1 study in Autism Spectrum DisorderNCT06557902 · 33 enrolled · United States
  12. Oct 2, 2024Phase 1 study in SchizophreniaNCT06627413 · 52 enrolled · United States
  13. Nov 13, 20242 phase 3 studies in Irritability Associated With Autism Spectrum DisorderNCT06690398, NCT06706674
  14. Jul 30, 2026Phase 3 study in Depressive Disorder, MajorNCT07747389 · 585 planned

Ahead

  1. Apr 5, 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT05850689
  2. Jun 21, 2027Primary completion: phase 3 study in Irritability Associated With Autism Spectrum DisorderNCT06706674
  3. Jun 21, 2027Primary completion: phase 3 study in Irritability Associated With Autism Spectrum DisorderNCT06690398
  4. Sep 20, 2029Primary completion: phase 3 study in Depressive Disorder, MajorNCT07747389

TargetBeta

“Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist; Serotonin transporter inhibitor”ChEMBL 37, by rule

Studies

All 25 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07747389Depressive Disorder, Major3Not yet recruitingSep 20, 2029585
NCT06706674Irritability Associated With Autism Spectrum Disorder · United States3RecruitingJun 21, 2027160
NCT06690398Irritability Associated With Autism Spectrum Disorder · United States, Serbia3RecruitingJun 21, 2027160
NCT06627413Schizophrenia · United States1CompletedNov 20, 202552
NCT06557902Autism Spectrum Disorder · United States1CompletedNov 26, 202533
NCT06462612Bipolar Disorder · United States, Bulgaria, Romania and more3CompletedMay 15, 2026351
NCT06462586Bipolar Disorder · United States, Bulgaria, Croatia and more3CompletedFeb 24, 2026354
NCT06372964Bipolar Disorder · United States, Colombia, India and more3RecruitingOct 31, 2031384
NCT06229210Schizophrenia · United States, Colombia, Serbia3RecruitingApr 28, 2032300
NCT05850689Depressive Disorder, Major · United States, Bulgaria, France and more3RecruitingApr 5, 2027470
NCT05061719Depressive Disorder, Major · United States, Bulgaria, Czechia and more3CompletedOct 14, 2024812
NCT05061706Depressive Disorder, Major · United States, Argentina, Bulgaria and more3CompletedApr 12, 2024480
NCT04985942Depressive Disorder, Major · United States, Bulgaria, Czechia and more3CompletedFeb 22, 2024485
NCT04959032Schizophrenia · United States, Bulgaria, Poland and more3CompletedJul 25, 2024592
NCT04779177Schizophrenia · United States1CompletedJul 30, 202226
NCT04285515Bipolar Disorder · United States, Bulgaria, Russian Federation and more3CompletedNov 30, 2022488
NCT03249376Bipolar Disorder · United States, Bulgaria, Colombia and more3CompletedMar 1, 2019381
NCT02817906Aberrant Motor Behavior in Dementia · United States3TerminatedJan 30, 2019177
NCT02600507Bipolar Disorder · United States, Bulgaria, Russian Federation and more3CompletedJul 2, 2020529
NCT02600494Bipolar Disorder · United States3CompletedJan 28, 2019554
NCT02469155Schizophrenia · United States3CompletedAug 2016696
NCT02288845Schizophrenia · United States2CompletedJul 201514
NCT02282761Schizophrenia · United States3CompletedJul 2015450
NCT02078310Alzheimer Disease · United States2CompletedAug 201435
NCT01499563Schizophrenia · United States2CompletedAug 2013335

How it is read

Names in the registry

  • “Lumateperone”, 11 entries
  • “ITI-007”, 7 entries
  • “Lumateperone high dose”, 2 entries
  • “Lumateperone low dose”, 2 entries
  • “Lumateperone 42 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.